The in vitro activity of ciprofloxacin, ofloxacin, amifloxacin, and norfloxacin against 22 clinical isolates of Mycobacterium tuberculosis was evaluated by agar dilution. The MICs for 90% of the isolates of ciprofloxacin and ofloxacin were 0.5 and 1 ,ug/ml, respectively. Amifloxacin and norfloxacin were less active. The MICs for 90% of the isolates of ciprofloxacin and ofloxacin against 20 clinical isolates of Mycobacterium intracellulare were determined by agar dilution to be 2 and 8 ,ug/ml, respectively.
The 4-quinolones are heterocyclic carbonic acid derivatives structurally similar to nalidixic acid. They have a broad spectrum of activity against aerobic and anaerobic grampositive and gram-negative organisms. The evaluation of the in vitro activity of 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare is part of an ongoing effort by our 4 ,ug/ml ( Table  2 ). The concentration which produced 99% killing was usually one or two dilutions higher than was the corresponding MIC. The MICs for P. aeruginosa were determined to be 0.5 jig/ml by broth dilution and 1 p.g/ml by agar dilution.
DISCUSSION
Additional agents for treating mycobacterial diseases are needed. The treatment of multi-drug-resistant M. tuberculosis infections is often difficult, since many of the "secondline" agents are not well tolerated. There is a greater need for effective drugs against M. intracellulare, an organism for which optimal therapy has yet to be defined (4, 10) . The published data on the in vitro activity of the 4-quinolones against M. tuberculosis and M. intracellulare are limited. Gay et al. (6) reported the activities of ciprofloxacin and norfloxacin against 100 mycobacterial isolates, including 20 isolates each of M. tuberculosis and M. intracellulare. These investigators found an MIC50 and an MIC9o of ciprofloxacin for M. tuberculosis of 0.5 and 1 jig/ml, respectively, values which are similar to ours. The MIC50 and the MIC9o for M. intracellulare were 2 and 16 ,ug/ml, respectively, values which were somewhat higher than those we observed. This may have resulted from different methodologies. Gaya and Chadwick (7) found that the MICs of ciprofloxacin were < 4 pLg/ml for all M. tuberculosis isolates but >16 ,ug/ml for most M. intracellulare isolates. Since their methodology was quite different from ours, a direct comparison with their results is difficult. Tsukamura reported in vitro testing of ofloxacin against M. tuberculosis (13, 14) and Mycobacterium avium and M. intracellulare (13) . His results agree with those of the present study in regard to M. tuberculosis; however, he found that M. intracellulare was inhibited by lower concentrations of ofloxacin than was M. avium (33 of 38 M. intracellulare isolates were inhibited by 2.5 ,ug/ml, and 17 of 20 M. avium isolates were inhibited by 10 ,ug/ml).
Tsukamura et al. (15) studied in vivo activity of ofloxacin, 300 mg given to patients daily, in the treatment of multi-drugresistant cavitary pulmonary tuberculosis. These investigators felt that ofloxacin was less effective than rifampin but more effective than kanamycin, ethionamide, or cycloserine.
Ciprofloxacin achieves peak concentrations in serum of 2 to 3 ,ug/ml after a 500-mg oral dose (2, 5, 9), 3.4 to 4.2 ,ug/ml after a 750-mg oral dose (8) , and 2 ,ug/ml after a 100-mg intravenous bolus (17). Ofloxacin achieves a peak level in serum of 11 ,ug/ml after a 600-mg oral dose (11) . Peak levels in serum of 4 ,ug/ml are obtainable after a 1,600-mg oral dose of norfloxacin (12) . Pharmacokinetic data for amifloxacin are not available.
Although ciprofloxacin is more active in vitro than ofloxacin against M. tuberculosis and M. intracellulare, the higher levels achievable in serum with ofloxacin make it difficult to predict which might be more active in vivo. The peak levels in serum serious adverse effects reported (1, 15 
